COVID-19 Symptoms by Variant Period in the North Carolina COVID-19 Community Research Partnership, North Carolina, USA-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

COVID-19 Symptoms by Variant Period in the North Carolina COVID-19 Community Research Partnership, North Carolina, USA

Published:2023-01 Issue:1 Volume:29 Page:207-211
ISSN:1080-6040
Container-title:Emerging Infectious Diseases
language:
Short-container-title:Emerg. Infect. Dis.

Author:

DeWitt Michael E.,Tjaden Ashley H.,Herrington David,Schieffelin John,Gibbs Michael,Weintraub William S.,Sanders John W.,Edelstein Sharon L.,

Publisher

Centers for Disease Control and Prevention (CDC)

Subject

Infectious Diseases,Microbiology (medical),Epidemiology

Reference15 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.;Huang;Lancet,2020

2. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.;Lewnard;Nat Med,2022

3. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.;Twohig;Lancet Infect Dis,2022

4. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools.;Ulyte;BMJ,2021

5. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021.;Brandal;Euro Surveill,2021

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Long Coronavirus Disease (COVID) Cough: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study;Engineering;2024-09

2. New variants of COVID‐19 (XBB.1.5 and XBB.1.16, the “Arcturus”): A review of highly questioned concerns, a brief comparison between different peaks in the COVID‐19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at‐risk groups;Immunity, Inflammation and Disease;2024-06

3. Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial;Frontiers in Pharmacology;2024-05-27

4. The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period;Pathogens;2024-03-20

5. Acute and persistent symptoms of COVID-19 infection in school-aged children: a retrospective study from China;BMC Public Health;2024-02-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3